+ All Categories

Home > Documents > €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681...

€¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681...

Date post:	13-Mar-2020
Category:	Documents
Upload:	others
View:	0 times
Download:	0 times

Download Report this document

Share this document with a friend

Embed Size (px):

74

Transcript

Page 1: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 2: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 3: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 4: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 5: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 6: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 7: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 8: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 9: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 10: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 11: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 12: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 13: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 14: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 15: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 16: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 17: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 18: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 19: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 20: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 21: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 22: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 23: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 24: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 25: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 26: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 27: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 28: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 29: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 30: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 31: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 32: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 33: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 34: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 35: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 36: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 37: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 38: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 39: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 40: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 41: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 42: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 43: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 44: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 45: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 46: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 47: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 48: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 49: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 50: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 51: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 52: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 53: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 54: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 55: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 56: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 57: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 58: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 59: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 60: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 61: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 62: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 63: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 64: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 65: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 66: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 67: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 68: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 69: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 70: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 71: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 72: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 73: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Page 74: €¦ · Control in year 1 Evolocumab in year 2+ N: 325 216 20 subjects did not receive IP 681 Study 651 30 632 599 33 Discontinued IP 5 consent withdrawn 8 adverse event 1 pregnancy

Recommended

REPATHA (ri-PAth-a) (evolocumab) injection, for ... · REPATHA ® (ri-PAth-a) (evolocumab) injection, for subcutaneous use What is REPATHA? REPATHA is an injectable prescription medicine

WARNING! DISCONTINUED

INSTRUCTION MANUAL Discontinued

SPYDERCO - 2012 Discontinued Products.pdf

(Discontinued) DMC10 with (Discontinued) NSF DMC10X 013746 ... · DMC10 /DMC 20 with Timer (Discontinued) DMC10X /DMC10 Canada (Discontinued) Unit Information 1 Amp. Butterfly Agitator

2014 Wiley Valentine Discontinued Items

Swarovski Discontinued 2014

Financial reporting developments - Discontinued operations

Discontinued Items

- DISCONTINUED PRODUCT - LogiCORE™ IP Generic Framing Procedure … · 2019-10-17 · The Generic Framing Procedure v2.1 Getting Started Guide provides information about generating

List of Discontinued Agencies

LOGO DISCONTINUED LOGO DISCONTINUED · 2-Color 2-Color 2-Color 3-Color 2-Color 817 820 2-Color 816 825 834 839 ... 2-Color 2-Color 2-Color 2-Color 2-Color LOGO DISCONTINUED LOGO DISCONTINUED

DISCONTINUED DISCONTINUED DISCONTINUED

Discontinued - Ballasts | Emergency | Modules

Cardiovascular Efficacy & Safety of Evolocumab in … Diabetes EASD Final...Cardiovascular Efficacy & Safety of Evolocumab in Diabetes, ... Members unaware of treatment assignment

Inclisiran and the ORION programme · Total AMG 145 (evolocumab) Free PCSK9 Free PCSK9 concentration (ng/mL) Free evolocumab concentration (ng/mL x 0.01) LDL-C Stein EA & RaalFJ Annu.

All Devices Discontinued!

spiral.imperial.ac.uk€¦ · Web viewClinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease:An Analysis from FOURIER. Short Title: Benefit of Evolocumab